Readoutin 226d
Biohaven Ltd. — Taldefgrobep
Phase 2 topline data expected (monotherapy and GLP-1 combination arms).
- Date
- H2 2027
- Type
- Readout
- Ticker
- BHVN
- Indication
- Obesity
Readoutin 226d
Phase 2 topline data expected (monotherapy and GLP-1 combination arms).
The weekly brief is free. Pro adds reminders 7 days and 1 day before.